Genmab (Otc) (GMAB) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab (GMAB) has launched a first-in-human Phase 1 trial titled “First-in-human, Open-label, Phase 1 Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Select Advanced Malignant Solid Tumors.” The study aims to test safety, find the best dose, and look for early signs of benefit in people with advanced solid tumors who have few remaining treatment options.
The treatment under review is GEN1079, an experimental antibody drug given as a concentrated solution. It is designed to target cancer cells in advanced solid tumors, with the goal of slowing or shrinking disease while keeping side effects manageable.
This is an interventional cancer trial where all enrolled patients receive GEN1079 rather than placebo. The design is open label with no blinding, and patients are sequentially assigned to different dose groups, with some randomization between dose levels in later parts of the trial to refine dosing for treatment use.
The study is listed as recruiting, with initial submission on 28 Jan 2026 and the latest update filed on 16 Feb 2026, showing active trial setup. Participant follow-up can last from about 33 to 67 weeks, meaning key safety and early activity data should emerge over the next few years before full completion.
For investors, this update adds another early pipeline asset to Genmab’s oncology portfolio, which could support long-term growth expectations if GEN1079 shows a clean safety profile and early tumor responses. While Phase 1 risk is high and near-term revenue impact is limited, positive signals could improve sentiment toward GMAB relative to other antibody-focused cancer players and help diversify risk away from its current key products.
The GEN1079 study remains ongoing and recently updated, with further details available on the ClinicalTrials portal.
To learn more about GMAB’s potential, visit the Genmab (Otc) drug pipeline page.